Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för regorafenib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

12 träffar

Bibliografisk träff 2013-02-01

Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery.

Carr BI, Cavallini A, Lippolis C, D'Alessandro R, Messa C, Refolo MG, Tafaro A.

J Cell Physiol · research-article; journal article · DOI 10.1002/jcp.24148

Bibliografisk träff 2012-09-06

Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial.

Eisen T, Joensuu H, Nathan PD, Harper PG, Wojtukiewicz MZ, Nicholson S, Bahl A, Tomczak P, Pyrhonen S, Fife K, Bono P, Boxall J, Wagner A, Jeffers M, Lin T, Quinn DI.

Lancet Oncol · clinical trial, phase ii; research support, non-u.s. gov't; journal article · DOI 10.1016/s1470-2045(12)70364-9

Bibliografisk träff 2012-07-12

Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1.

de Jesus-Gonzalez N, Robinson E, Penchev R, von Mehren M, Heinrich MC, Tap W, Wang Q, Demetri G, George S, Humphreys BD.

Am J Hypertens · research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1038/ajh.2012.97

Bibliografisk träff 2012-06-01

Regorafenib for cancer.

Strumberg D, Schultheis B.

Expert Opin Investig Drugs · review; journal article · DOI 10.1517/13543784.2012.684752

Bibliografisk träff 2012-05-22

Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer.

Troiani T, Martinelli E, Orditura M, De Vita F, Ciardiello F, Morgillo F.

Expert Opin Investig Drugs · review; journal article · DOI 10.1517/13543784.2012.689287

Bibliografisk träff 2012-05-21

Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.

George S, Wang Q, Heinrich MC, Corless CL, Zhu M, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Tap WD, Yap JT, Van den Abbeele AD, Manola JB, Solomon SM, Fletcher JA, von Mehren M, Demetri GD.

J Clin Oncol · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1200/jco.2011.39.9394

Bibliografisk träff 2012-05-08

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.

Strumberg D, Scheulen ME, Schultheis B, Richly H, Frost A, Büchert M, Christensen O, Jeffers M, Heinig R, Boix O, Mross K.

Br J Cancer · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1038/bjc.2012.153

Bibliografisk träff 2012-05-01

Regorafenib in metastatic colorectal cancer.

Grothey A.

Clin Adv Hematol Oncol · journal article

Bibliografisk träff 2012-03-15

A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors.

Mross K, Frost A, Steinbild S, Hedbom S, Büchert M, Fasol U, Unger C, Krätzschmar J, Heinig R, Boix O, Christensen O.

Clin Cancer Res · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1158/1078-0432.ccr-11-1900

Bibliografisk träff 2011-07-12

An update on the current and emerging targeted agents in metastatic colorectal cancer.

Chu E.

Clin Colorectal Cancer · research support, non-u.s. gov't; review; journal article · DOI 10.1016/j.clcc.2011.05.005

Bibliografisk träff 2011-04-22

Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.

Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, Thierauch KH, Zopf D.

Int J Cancer · journal article · DOI 10.1002/ijc.25864

Bibliografisk träff 2011-04-01

Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors.

Demetri GD.

Semin Oncol · research support, non-u.s. gov't; review; journal article · DOI 10.1053/j.seminoncol.2011.01.018